Compare VICI Properties Inc (VICI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VICI Properties Inc vs Viatris Inc — how do they compare? VICI Properties Inc trades at $26.75 (market cap $29.55B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: VICI Properties Inc is the larger of the two by market cap, and VICI Properties Inc pays the higher dividend (6.71%). Which is the better fit depends on your goals.
| VICI | VTRS | |
|---|---|---|
Market Cap | $29.55B | $19.79B |
Sector | Real Estate | Health |
52-Week High | $33.93 | $17.39 |
52-Week Low | $25.94 | $8.74 |
Enterprise Value | $46.77B | $32.00B |
Dividend Yield | 6.71% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VICI Properties trades at $26.83, down slightly (-0.15%) on the day. The stock shows strong fundamentals with a P/E of 9.19, net income margin of 76.83%, and consistent earnings beats in recent quarters. Technical indicators are mixed with an overall bullish signal but bearish moving averages. Recent news highlights institutional activity with CalPERS reducing its stake while Aviance Capital Partners initiated a new position.
VICI offers a compelling investment case with attractive valuation metrics, robust profitability, and a 6.62% dividend yield. However, risks include tenant concentration with Caesars/MGM accounting for 70% of rent and potential lease uncertainties from recent buyout discussions. Analyst consensus remains strongly bullish with a $29.00 price target suggesting 8% upside potential.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
